Covid-19 Research

Research Article

OCLC Number/Unique Identifier: 9227639280

Prevention of Opioid Addiction

Medicine Group    Start Submission

Stephanie A Ihezie and Nachum Dafny*

Volume2-Issue8
Dates: Received: 2021-07-17 | Accepted: 2021-08-27 | Published: 2021-08-31
Pages: 731-740

Abstract

Opioid addiction is classified as a Substance Use Disorder (SUD), a complex and chronic health condition with physical, social, and psychological consequences. While there is no cure for it, we present a novel approach towards preventing a hallmark feature of addiction-- the opiate withdrawal syndrome. Opioids exert numerous effects, acutely and chronically, on the nervous system with physical dependence, tolerance, and withdrawal being the most adverse chronic features. The degree of opioid dependence can be quantified by the frequency and/or intensity of the behavioral expression of withdrawal seen after abrupt termination of opioid consumption or after treatment with an opioid antagonist such as naloxone. Although the Central Nervous System (CNS) is the primary area of opioid impact, the involvement of the immune system in modifying CNS phenomena was suggested nearly two centuries ago and proved by several groups within the last few decades. Through a series of studies with immunomodulators alpha interferon, cyclosporine A, and cortisol, preclinical experiments show that administration of these agents prior to chronic morphine exposure prevents the expression of opiate withdrawal a hallmark feature of addiction. This review provides updates on current developments in the management of the opioid epidemic and an overview of studies on preventative immunomodulation prior to repetitive opioid administration as a means of addressing one of the underlying symptomatology driving the epidemic.

FullText HTML FullText PDF DOI: 10.37871/jbres1304


Certificate of Publication




Copyright

© 2021 Ihezie SA, et al. Distributed under Creative Commons CC-BY 4.0

How to cite this article

Ihezie SA, Dafny N. Prevention of Opioid Addiction. J Biomed Res Environ Sci. 2021 Aug 31; 2(8): 731-740. doi: 10.37871/jbres1304, Article ID: JBRES1304, Available at: https://www.jelsciences.com/articles/jbres1304.pdf


Subject area(s)

References


  1. Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol. 2008 Oct;16(5):405-416. doi: 10.1037/a0013628. PMID: 18837637; PMCID: PMC2711509.
  2. Khademi H, Kamangar F, Brennan P, Malekzadeh R. Opioid Therapy and its Side Effects: A Review. Arch Iran Med. 2016 Dec;19(12):870-876. PMID: 27998163.
  3. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2006 Feb 1;81(2):103-107. doi: 10.1016/j.drugalcdep.2005.05.009. Epub 2005 Jul 14. PMID: 16023304.
  4. Alpert A, Powell D, Pacula RL. Supply-side drug policy in the presence of substitutes: Evidence from the introduction of abuse-deterrent opioids. American Economic Journal: Economic Policy. 2018;10(4):1–35. Doi: 10.1257/pol.20170082
  5. Schnell M. The Opioid Crisis : Tragedy, Treatments and Trade-offs. SIEPR Report. 2019:1-4.
  6. Muhuri P, Gfroerer J, Davies M. Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States. CBHSQ Data Rev. 2013.
  7. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015 Apr;156(4):569-576. doi: 10.1097/01.j.pain.0000460357.01998.f1. PMID: 25785523.
  8. Hedden SL, Kennet J, Lipari R, Medley G, Tice P, Copello EA, Kroutil LA. Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. 2015.
  9. Hedden SL, Kennet J, Lipari R, Medley G, Tice P, Copello EA, Kroutil LA. Key Substance Use and Mental Health Indicators in the United States: Results from the 2015 National Survey on Drug Use and Health. 2016.
  10. Rudd RA, Seth P, David F, Scholl L. Increases in Drug and Opioid-Involved Overdose Deaths - United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016 Dec 30;65(50-51):1445-1452. doi: 10.15585/mmwr.mm655051e1. PMID: 28033313.
  11. Hedegaard H, Warner M, Miniño AM. Drug Overdose Deaths in the United States, 1999-2016. 2017.
  12. Hedegaard H, Miniño AM, Warner M. Drug Overdose Deaths in the United States, 1999-2018. 2020.
  13. Pitt AL, Humphreys K, Brandeau ML. Modeling Health Benefits and Harms of Public Policy Responses to the US Opioid Epidemic. Am J Public Health. 2018 Oct;108(10):1394-1400. doi: 10.2105/AJPH.2018.304590. Epub 2018 Aug 23. PMID: 30138057; PMCID: PMC6137764.
  14. Hofford RS, Russo SJ, Kiraly DD. Neuroimmune mechanisms of psychostimulant and opioid use disorders. Eur J Neurosci. 2019 Aug;50(3):2562-2573. doi: 10.1111/ejn.14143. Epub 2018 Sep 26. PMID: 30179286; PMCID: PMC6531363.
  15. Cicero TJ, Meyer ER. Morphine pellet implantation in rats: quantitative assessment of tolerance and dependence. J Pharmacol Exp Ther. 1973 Feb;184(2):404-408. PMID: 4734581.
  16. Wei E, Way E. Application of the pellet implantation technique for the assessment of tolerance and physical dependence in the rodent. Marcel Dekker New York. 1975:243-259.
  17. Dafny N. Modification of morphine withdrawal by interferon. Life Sci. 1983 Jan 24;32(4):303-305. doi: 10.1016/0024-3205(83)90074-7. PMID: 6681856.
  18. Kalant H. Opium revisited: a brief review of its nature, composition, non-medical use and relative risks. Addiction. 1997 Mar;92(3):267-77. PMID: 9219389.
  19. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011 Mar-Apr;14(2):145-161. PMID: 21412369.
  20. Groninger H, Vijayan J. Pharmacologic management of pain at the end of life. Am Fam Physician. 2014 Jul 1;90(1):26-32. PMID: 25077499.
  21. Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW, Alexander GC. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015 Mar 18;36:559-574. doi: 10.1146/annurev-publhealth-031914-122957. Epub 2015 Jan 12. PMID: 25581144.
  22. Liang X, Liu R, Chen C, Ji F, Li T. Opioid System Modulates the Immune Function: A Review. Transl Perioper Pain Med. 2016;1(1):5-13. PMID: 26985446; PMCID: PMC4790459.
  23. NIDA. How effective are medications to treat opioid use disorder? National Institute on Drug Abuse (NIDA). 2020.
  24. Weiss S, Volkow ND. 129th Meeting Minutes | National Institute on Drug Abuse (NIDA). 2018.
  25. Lofwall MR, Walsh SL, Nunes EV, Bailey GL, Sigmon SC, Kampman KM, Frost M, Tiberg F, Linden M, Sheldon B, Oosman S, Peterson S, Chen M, Kim S. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial. JAMA Intern Med. 2018 Jun 1;178(6):764-773. doi: 10.1001/jamainternmed.2018.1052. PMID: 29799968; PMCID: PMC6145749.
  26. Tompkins CNE, Neale J, Strang J. Opioid users’ willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder. J Subst Abuse Treat. 2019 Sep;104:64-71. doi: 10.1016/j.jsat.2019.06.007. Epub 2019 Jun 9. PMID: 31370986.
  27. Wybran J, Appelboom T, Famaey JP, Govaerts A. Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human blood T lymphocytes. J Immunol. 1979 Sep;123(3):1068-1070. PMID: 224107.
  28. Sacerdote P, Limiroli E, Gaspani L. Experimental evidence for immunomodulatory effects of opioids. Adv Exp Med Biol. 2003;521:106-16. PMID: 12617569.
  29. Plein LM, Rittner HL. Opioids and the immune system - friend or foe. Br J Pharmacol. 2018 Jul;175(14):2717-2725. doi: 10.1111/bph.13750. Epub 2017 Mar 23. PMID: 28213891; PMCID: PMC6016673.
  30. Kohno M, Link J, Dennis LE, McCready H, Huckans M, Hoffman WF, Loftis JM. Neuroinflammation in addiction: A review of neuroimaging studies and potential immunotherapies. Pharmacol Biochem Behav. 2019 Apr;179:34-42. doi: 10.1016/j.pbb.2019.01.007. Epub 2019 Jan 26. PMID: 30695700; PMCID: PMC6637953.
  31. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain Physician. 2008 Mar;11(2 Suppl):S105-120. PMID: 18443635.
  32. Holden J, Jeong Y, Forrest JM. The endogenous opioid system and clinical pain management. AACN Clinical Issues. 2005;16(3):291-301. https://tinyurl.com/dwkvjfym
  33. Sacerdote P. Opioids and the immune system. Palliat Med. 2006;20 Suppl 1:s9-15. PMID: 16764216.
  34. Sacerdote P, Franchi S, Gerra G, Leccese V, Panerai AE, Somaini L. Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function. Brain Behav Immun. 2008 May;22(4):606-613. doi: 10.1016/j.bbi.2007.12.013. Epub 2008 Feb 21. PMID: 18294814.
  35. Ling W. Buprenorphine for opioid dependence. Expert Rev Neurother. 2009 May;9(5):609-616. doi: 10.1586/ern.09.26. PMID: 19402772; PMCID: PMC4151622.
  36. Gomez-Flores R, Weber RJ. Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray. Immunopharmacology. 2000 Jul 20;48(2):145-156. doi: 10.1016/s0162-3109(00)00198-3. PMID: 10936512
  37. Gaspani L, Bianchi M, Limiroli E, Panerai AE, Sacerdote P. The analgesic drug tramadol prevents the effect of surgery on natural killer cell activity and metastatic colonization in rats. J Neuroimmunol. 2002 Aug;129(1-2):18-24. doi: 10.1016/s0165-5728(02)00165-0. PMID: 12161016.
  38. Shavit Y, Ben-Eliyahu S, Zeidel A, Beilin B. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. Neuroimmunomodulation. 2004;11(4):255-260. doi: 10.1159/000078444. PMID: 15249732.
  39. Martucci C, Panerai AE, Sacerdote P. Chronic fentanyl or buprenorphine infusion in the mouse: Similar analgesic profile but different effects on immune responses. Pain. 2004;110(1–2):385-392. doi: 10.1016/j.pain.2004.04.020
  40. Dafny N, Burks TF, Bergmann F. Dose effects of morphine on the spontaneous unit activity recorded from the thalamus, hypothalamus, septum, hippocampus, reticular formation, central gray, and caudate nucleus. J Neurosci Res. 1983;9(2):115-126. doi: 10.1002/jnr.490090203. PMID: 6842623.
  41. Dougherty PM, Aronowski J, Samorajski T, Dafny N. Opiate antinociception is altered by immunemodification: the effect of interferon, cyclosporine and radiation-induced immune suppression upon acute and long-term morphine activity. Brain Res. 1986 Oct 22;385(2):401-404. doi: 10.1016/0006-8993(86)91091-7. PMID: 3779401.
  42. Dougherty PM, Dafny N. Cyclosporine affects central nervous system opioid activity via direct and indirect means. Brain Behav Immun. 1988 Sep;2(3):242-253. doi: 10.1016/0889-1591(88)90026-8. PMID: 3242657.
  43. Dafny N, Pellis NR. Evidence that opiate addiction is in part an immune response. Destruction of the immune system by irradiation-altered opiate withdrawal. Neuropharmacology. 1986 Aug;25(8):815-818. doi: 10.1016/0028-3908(86)90003-1. PMID: 3774111.
  44. Bidlack JM. Detection and function of opioid receptors on cells from the immune system. Clinical and Diagnostic Laboratory Immunology. American Society for Microbiology (ASM). 2000. Doi: 10.1128/CDLI.7.5.719-723.2000
  45. Zhu JW, Liu FL, Mu D, Deng DY, Zheng YT. Heroin use is associated with lower levels of restriction factors and type I interferon expression and facilitates HIV-1 replication. Microbes Infect. 2017 Apr-May;19(4-5):288-294. doi: 10.1016/j.micinf.2017.01.002. Epub 2017 Jan 16. PMID: 28104465.
  46. Eisenstein TK. The Role of Opioid Receptors in Immune System Function. Front Immunol. 2019 Dec 20;10:2904. doi: 10.3389/fimmu.2019.02904. PMID: 31921165; PMCID: PMC6934131.
  47. Donahoe RM, Vlahov D. Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J Neuroimmunol. 1998 Mar 15;83(1-2):77-87. doi: 10.1016/s0165-5728(97)00224-5. PMID: 9610676.
  48. Risdahl JM, Khanna KV, Peterson PK, Molitor TW. Opiates and infection. J Neuroimmunol. 1998 Mar 15;83(1-2):4-18. doi: 10.1016/s0165-5728(97)00216-6. PMID: 9610668.
  49. Watkins LR, Hutchinson MR, Johnston IN, Maier SF. Glia: novel counter-regulators of opioid analgesia. Trends Neurosci. 2005 Dec;28(12):661-669. doi: 10.1016/j.tins.2005.10.001. Epub 2005 Oct 24. PMID: 16246435.
  50. Hidalgo JJ. The role of glial cells in drug abuse. Current Drug Abuse Reviews. 2009;2(1):76–82. Doi: 10.2174/1874473710902010076
  51. Coller JK, Hutchinson MR. Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence. Pharmacol Ther. 2012 May;134(2):219-245. doi: 10.1016/j.pharmthera.2012.01.008. Epub 2012 Feb 1. PMID: 22316499.
  52. Evans CJ, Cahill CM. Neurobiology of opioid dependence in creating addiction vulnerability. F1000Res. 2016 Jul 19;5:F1000 Faculty Rev-1748. doi: 10.12688/f1000research.8369.1. PMID: 27508068; PMCID: PMC4955026.
  53. Sofroniew MV. Multiple roles for astrocytes as effectors of cytokines and inflammatory mediators. Neuroscientist. 2014 Apr;20(2):160-172. doi: 10.1177/1073858413504466. Epub 2013 Oct 8. PMID: 24106265.
  54. Salter MW, Stevens B. Microglia emerge as central players in brain disease. Nat Med. 2017 Sep 8;23(9):1018-1027. doi: 10.1038/nm.4397. PMID: 28886007.
  55. McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend. 2001 Apr 1;62(2):111-123. doi: 10.1016/s0376-8716(00)00181-2. PMID: 11245967.
  56. Harricharan R, Abboussi O, Daniels WMU. Addiction: A deregulation of satiety inflammation processes. Progress in Brain Research. 2016:235. Doi10.1016/bs.pbr 2017.07.012
  57. Zhang H, Largent-Milnes TM, Vanderah TW. Glial neuroimmune signaling in opioid reward. Brain Res Bull. 2020 Feb;155:102-111. doi: 10.1016/j.brainresbull.2019.11.012. Epub 2019 Nov 29. PMID: 31790721; PMCID: PMC6946383.
  58. Dafny N, Dougherty PM, Pellis NR. The immune system and opiate withdrawal. Int J Immunopharmacol. 1989;11(4):371-375. doi: 10.1016/0192-0561(89)90083-0. PMID: 2674032.
  59. Dougherty PM, Dafny N. Muramyl-dipeptide, a macrophage-derived cytokine, alters neuronal activity in hypothalamus and hippocampus but not in the dorsal raphe/periaqueductal gray of rats. J Neuroimmunol. 1990 Aug;28(3):201-208. doi: 10.1016/0165-5728(90)90013-d. PMID: 2373761.
  60. Dougherty PM, Aronowski J, Drath D, Dafny N. Evidence of neuro-immunologic interactions: cyclosporine modifies opiate withdrawal by effects on the brain and immune components. J Neuroimmunol. 1987 Jan;13(3):331-342. doi: 10.1016/0165-5728(87)90068-3. PMID: 3793881.
  61. Dougherty PM, Drath DB, Dafny N. Evidence of an immune system to brain communication axis that affects central opioid functions: muramyl peptides attenuate opiate withdrawal. Eur J Pharmacol. 1987 Sep 11;141(2):253-260. doi: 10.1016/0014-2999(87)90270-6. PMID: 2824218.
  62. Pestka S, Baron S. Definition and classification of the interferons. Methods Enzymol. 1981;78(Pt A):3-14. doi: 10.1016/0076-6879(81)78091-1. PMID: 6173606.
  63. Lengyel P. Biochemistry of interferons and their actions. Annu Rev Biochem. 1982;51:251-82. doi: 10.1146/annurev.bi.51.070182.001343. PMID: 6180680.
  64. Dafny N, Lincoln J. The Role of Interferons on the Central Nervous System in Health and Disease. In Reference Module in Biomedical Sciences. Elsevier. 2016. Doi: 10.1016/b978-0-12-801238-3.99446-7.
  65. Roosth J, Pollard RB, Brown SL, Meyer WJ 3rd. Cortisol stimulation by recombinant interferon-alpha 2. J Neuroimmunol. 1986 Oct;12(4):311-316. doi: 10.1016/0165-5728(86)90037-8. PMID: 3760157.
  66. Dafny N. Is interferon-α a neuromodulator? Brain Research Reviews. Elsevier BV. 1998. doi: 10.1016/S0165-0173(97)00029-5
  67. Blalock JE, Smith EM. Human leukocyte interferon: Structural and biological relatedness to adrenocorticotropic hormone and endorphins. Proc Natl Acad Sci U S A. 1980 Oct;77(10):5972-5974. doi: 10.1073/pnas.77.10.5972. PMID: 6160589; PMCID: PMC350194.
  68. Dafny N, Rigor BM. Characterization of unit activity recorded from septum, thalamus, and caudate following incremental opiate treatment. J Neurosci Res. 1980;5(2):117-127. doi: 10.1002/jnr.490050203. PMID: 7401192.
  69. Dafny N, Reyes-Vazquez C. Three different types of alpha-interferons alter naloxone-induced abstinence in morphine-addicted rats. Immunopharmacology. 1985 Feb;9(1):13-17. doi: 10.1016/0162-3109(85)90041-4. PMID: 4039302.
  70. Dafny N, Wagle VG, Drath DB. Cyclosporine alters opiate withdrawal in rodents. Life Sci. 1985 May 6;36(18):1721-1726. doi: 10.1016/0024-3205(85)90554-5. PMID: 4039025.
  71. Dafny N, Zielinksi M, Reyes-Vazquez C. Alteration of morphine withdrawal to naloxone by interferon. Neuropeptides. 1983 Oct;3(6):453-463. doi: 10.1016/0143-4179(83)90036-7. PMID: 6420721.
  72. Vázquez, Cruz, Gómez, Dafny N. Interferon modulates central nervous system function. Brain Research. 2012. Doi: 10.1016/j.brainres.2011.09.061
  73. Reyes-Vazquez C, Mendoza-Fernandez V, Herrera-Ruiz M, Dafny N. Interferon modulates glucose-sensitive neurons in the hypothalamus. Exp Brain Res. 1997 Oct;116(3):519-524. doi: 10.1007/pl00005780. PMID: 9372301.
  74. Reyes-Vázquez C, Prieto-Gómez B, Dafny N. Alpha-interferon suppresses food intake and neuronal activity of the lateral hypothalamus. Neuropharmacology. 1994 Dec;33(12):1545-1552. doi: 10.1016/0028-3908(94)90128-7. PMID: 7760977.
  75. Capuron L, Pagnoni G, Drake DF, Woolwine BJ, Spivey JR, Crowe RJ, Votaw JR, Goodman MM, Miller AH. Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch Gen Psychiatry. 2012 Oct;69(10):1044-1053. doi: 10.1001/archgenpsychiatry.2011.2094. PMID: 23026954; PMCID: PMC3640298.
  76. Claussen M, Chong SL, Dafny N. Nucleus accumbens activity correlates to the animal’s behavioral response to acute and chronic methylphenidate. Physiol & Behav. 2014;129:85-94. https://tinyurl.com/rbc8pd27
  77. Claussen CM, Dafny N. Caudate neuronal recording in freely behaving animals following acute and chronic dose response methylphenidate exposure. Pharmacol Biochem Behav. 2015 Sep;136:21-30. doi: 10.1016/j.pbb.2015.06.003. Epub 2015 Jun 20. PMID: 26101057; PMCID: PMC4743873.
  78. Dafny N. Multiunit recording from medial basal hypothalamus following acute and chronic morphine treatment. Brain Res. 1980 May 26;190(2):584-592. doi: 10.1016/0006-8993(80)90304-2. PMID: 7189436.
  79. Dafny N. The hypothalamus exhibits electrophysiologic evidence for morphine tolerance and dependence. Exp Neurol. 1982 Jul;77(1):66-77. doi: 10.1016/0014-4886(82)90143-1. PMID: 7200913.
  80. Dafny N, Dong WQ, Prieto-Gomez C, Reyes-Vazquez C, Stanford J, Qiao JT. Lateral hypothalamus: Site involved in pain modulation. Neuroscience. 1996 Jan;70(2):449-460. doi: 10.1016/0306-4522(95)00358-4. PMID: 8848153.
  81. Dafny N, Gildenberg P. Morphine effects on spontaneous, nociceptive, antinociceptive and sensory evoked responses of parafasciculus thalami units in morphine naive and morphine dependent rats. Brain Res. 1984 Dec 3;323(1):11-20. doi: 10.1016/0006-8993(84)90260-9. PMID: 6543146.
  82. Dafny N, Marchand J, McClung R, Salamy J, Sands S, Wachtendorf H, Burks TF. Effects of morphine on sensory-evoked responses recorded from central gray, reticular formation, thalamus, hypothalamus, limbic system, basal ganglia, dorsal raphe, locus ceruleus, and pineal body. J Neurosci Res. 1980;5(5):399-412. doi: 10.1002/jnr.490050505. PMID: 7441794.
  83. Dafny N, Qiao JT. Habenular neuron responses to noxious input are modified by dorsal raphe stimulation. Neurol Res. 1990 Jun;12(2):117-121. doi: 10.1080/01616412.1990.11739929. PMID: 1974700.
  84. Dafny N, Rigor BM, Burks TF. Dependence and tolerance: multiunit recording from central gray, mesencephalic reticular formation, and medial thalamus in freely behaving rats. Exp Neurol. 1980 May;68(2):217-227. doi: 10.1016/0014-4886(80)90080-1. PMID: 7363992.
  85. Dafny N, Rigor BM. Characterization of unit activity recorded from septum, thalamus, and caudate following incremental opiate treatment. J Neurosci Res. 1980;5(2):117-127. doi: 10.1002/jnr.490050203. PMID: 7401192.
  86. Dafny N, Reyes-Vazquez C. Three different types of alpha-interferons alter naloxone-induced abstinence in morphine-addicted rats. Immunopharmacology. 1985 Feb;9(1):13-17. doi: 10.1016/0162-3109(85)90041-4. PMID: 4039302.
  87. Cupps TR, Fauci AS. Corticosteroid-mediated immunoregulation in man. Immunol Rev. 1982;65:133-155. doi: 10.1111/j.1600-065x.1982.tb00431.x. PMID: 6214495.
  88. Fauci AS, Dale DC. The effect of hydrocortisone on the kinetics of normal human lymphocytes. Blood. 1975 Aug;46(2):235-243. PMID: 1139040.
  89. Jones Z, Dafny N. Dose response effect of methylphenidate on ventral tegmental area neurons and animal behavior. Brain Res Bull. 2013 Jul;96:86-92. doi: 10.1016/j.brainresbull.2013.03.004. Epub 2013 May 4. PMID: 23651545.
  90. Jones Z, Dafny N. Acute and chronic dose-response effect of methylphenidate on ventral tegmental area neurons correlated with animal behavior. J Neural Transm (Vienna). 2014;121(3):327-345. doi: 10.1007/s00702-013-1101-2. Epub 2013 Nov 20. PMID: 24249696; PMCID: PMC4743876
  91. Karim TJ, Vázquez C, Dafny N. VTA neurons responding to MPD similarity to LC neurons: a concomitant behavioral and neuronal study of adolescent male rats. J of Neurophysiology. 2017;118:1501-1514.
  92. Karim TJ, Aksel C, Kharas N, Reyes-Vasquez C, Dafny N. Caudate nucleus neurons participate in methylphenidate function: Behavioral and neuronal recordings from freely behaving adolescent rats. Brain Res Bull. 2018 Sep;142:241-252. doi: 10.1016/j.brainresbull.2018.07.008. Epub 2018 Aug 10. PMID: 30016725.
  93. Kharas N, Whitt H, Reyes-Vasquez C, Dafny N. Methylphenidate modulates dorsal raphe neuronal activity: Behavioral and neuronal recordings from adolescent rats. Brain Res Bull. 2017 Jan;128:48-57. doi: 10.1016/j.brainresbull.2016.10.011. Epub 2016 Nov 23. PMID: 27889580; PMCID: PMC5224521.
  94. Kharas N, Reyes-Vazquez C, Dafny N. Locus coeruleus neuronal activity correlates with behavioral response to acute and chronic doses of methylphenidate (Ritalin) in adolescent rats. J Neural Transm (Vienna). 2017 Oct;124(10):1239-1250. doi: 10.1007/s00702-017-1760-5. Epub 2017 Jul 20. PMID: 28730316.
  95. Kanagalingam T, Solomon L, Vijeyakumaran M, Palikhe NS, Vliagoftis H, Cameron L. IL-2 modulates Th2 cell responses to glucocorticosteroid: A cause of persistent type 2 inflammation? Immun Inflamm Dis. 2019 Sep;7(3):112-124. doi: 10.1002/iid3.249. Epub 2019 Apr 17. PMID: 30994266; PMCID: PMC6688076.
  96. Montgomery SP, Dafny N. Cyclophosphamide and cortisol reduce the severity of morphine withdrawal. Int J Immunopharmacol. 1987;9(4):453-457. doi: 10.1016/0192-0561(87)90019-1. PMID: 3623770.
  97. Joseph JJ, Wang X, Spanakis E, Seeman T, Wand G, Needham B, Golden SH. Diurnal salivary cortisol, glycemia and insulin resistance: The multi-ethnic study of atherosclerosis. Psychoneuroendocrinology. 2015 Dec;62:327-335. doi: 10.1016/j.psyneuen.2015.08.021. Epub 2015 Aug 28. PMID: 26356041; PMCID: PMC4637243.
  98. Kelly J, Mangos G, Williamson P, Whitworth J. CORTISOL AND HYPERTENSION. Clinical and Experimental Pharmacology and Physiology. 1998;25(S1):S51–S56. Doi: 10.1111/j.1440-1681.1998.tb02301.x
  99. Law R, Clow A. Stress, the cortisol awakening response and cognitive function. Int Rev Neurobiol. 2020;150:187-217. doi: 10.1016/bs.irn.2020.01.001. Epub 2020 Mar 11. PMID: 32204832.
  100. Jefferies WMK. Cortisol and immunity. Medical Hypotheses. 1991. Doi: 10.1016/0306-9877(91)90212-H
  101. Eisenstein TK, Rahim RT, Feng P, Thingalaya NK, Meissler JJ. Effects of opioid tolerance and withdrawal on the immune system. J Neuroimmune Pharmacol. 2006 Sep;1(3):237-249. doi: 10.1007/s11481-006-9019-1. Epub 2006 May 23. PMID: 18040801.
  102. Al-Hashimi M, Scott SW, Thompson JP, Lambert DG. Opioids and immune modulation: more questions than answers. Br J Anaesth. 2013 Jul;111(1):80-88. doi: 10.1093/bja/aet153. PMID: 23794649.
  103. Manetti L, Cavagnini F, Martino E, Ambrogio A. Effects of cocaine on the hypothalamic-pituitary-adrenal axis. J Endocrinol Invest. 2014 Aug;37(8):701-708. doi: 10.1007/s40618-014-0091-8. Epub 2014 May 23. PMID: 24852417.
  104. Borel JF, Feurer C, Magnee C, Stahelin H. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology. 1977;32(6):1017–1025. https://tinyurl.com/mj8tzpr3
  105. Kahan BD. Cyclosporine: a powerful addition to the immunosuppressive armamentarium. Am J Kidney Dis. 1984 May;3(6):444-455. doi: 10.1016/s0272-6386(84)80009-8. PMID: 6372448.
  106. Andrus L, Lafferty KJ. Inhibition of T-cell activity by cyclosporin A. Scand J Immunol. 1981 May;15(5):449-458. doi: 10.1111/j.1365-3083.1982.tb00670.x. PMID: 6808656.
  107. Colombani PM, Robb A, Hess AD. Cyclosporin A binding to calmodulin: a possible site of action on T lymphocytes. Science. 1985 Apr 19;228(4697):337-339. doi: 10.1126/science.3885394. PMID: 3885394.
  108. Choi BJ, Whang KT. Change of hyperexcitability of hippocampus by cyclosporin A and its modulatory action by fentanyl. J Korean Med Sci. 2002 Feb;17(1):96-102. doi: 10.3346/jkms.2002.17.1.96. PMID: 11850597; PMCID: PMC3054821.
  109. Tsutsumi Y, Kanamori H, Tanaka J, Asaka M, Imamura M, Masauzi N. Withdrawal symptoms from transdermal fentanyl (TDF) after an allogeneic peripheral blood stem cell transplant (PBSCT). Pain Med. 2006 Mar-Apr;7(2):164-165. doi: 10.1111/j.1526-4637.2006.00107.x. PMID: 16634729.
  110. Yang ZZ, Li L, Wang L, Xu MC, An S, Jiang C, Gu JK, Wang ZJ, Yu LS, Zeng S. siRNA capsulated brain-targeted nanoparticles specifically knock down OATP2B1 in mice: a mechanism for acute morphine tolerance suppression. Sci Rep. 2016 Sep 15;6:33338. doi: 10.1038/srep33338. PMID: 27629937; PMCID: PMC5024137.
  111. Sanchez-Covarrubias L, Slosky LM, Thompson BJ, Zhang Y, Laracuente ML, DeMarco KM, Ronaldson PT, Davis TP. P-glycoprotein modulates morphine uptake into the CNS: a role for the non-steroidal anti-inflammatory drug diclofenac. PLoS One. 2014 Feb 10;9(2):e88516. doi: 10.1371/journal.pone.0088516. PMID: 24520393; PMCID: PMC3919782.
  112. Venkataraman SS, Claussen C, Joseph M, Dafny N. Concomitant behavioral and PFC neuronal activity recorded following dose-response protocol of MPD in adult male rats. Brain Res Bull. 2017 Apr;130:125-137. doi: 10.1016/j.brainresbull.2017.01.008. Epub 2017 Jan 19. PMID: 28111275.
  113. Venkataraman SS, Joseph M, Dafny N. Concomitant behavioral and prefrontal cortex neuronal responses following acute and chronic methylphenidate exposure in adolescent and adult rats. Brain Res Bull. 2019 Jan;144:200-212. doi: 10.1016/j.brainresbull.2018.11.004. Epub 2018 Nov 28. PMID: 30502401.
  114. Venkataraman SS, Joseph M, Dafny N. Concomitant behavioral and prefrontal cortex neuronal responses following acute and chronic methylphenidate exposure in adolescent and adult rats. Brain Res Bull. 2019 Jan;144:200-212. doi: 10.1016/j.brainresbull.2018.11.004. Epub 2018 Nov 28. PMID: 30502401.
  115. Venkataraman SS, Claussen CM, Kharas N, Dafny N. The prefrontal cortex and the caudate nucleus respond conjointly to methylphenidate (Ritalin). Concomitant behavioral and neuronal recording study. Brain Res Bull. 2020 Apr;157:77-89. doi: 10.1016/j.brainresbull.2019.10.009. Epub 2020 Jan 24. PMID: 31987926.
  116. Tang B, Dafny N. Behavioral and dorsal raphe neuronal activity following acute and chronic methylphenidate in freely behaving rats. Brain Res Bull. 2013 Sep;98:53-63. doi: 10.1016/j.brainresbull.2013.06.004. Epub 2013 Jul 22. PMID: 23886570.
  117. Tang B, Dafny N. Locus coeruleus neuronal and behavioral activity following acute and chronic methylphenidate. J of Brain Sciences. 2015;1:24-42.
  118. Tang B, Dafny N. Dorsal raphe neuronal activities are modulated by methylphenidate. J Neural Transm (Vienna). 2013 May;120(5):721-31. doi: 10.1007/s00702-012-0917-5. Epub 2012 Dec 27. PMID: 23269378; PMCID: PMC4036810.
  119. Berkowitz B, Spector S. Evidence for active immunity to morphine in mice. Science. 1972 Dec 22;178(4067):1290-1292. doi: 10.1126/science.178.4067.1290. PMID: 4640066.
  120. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992 Apr;13(4):136-142. doi: 10.1016/0167-5699(92)90111-J. PMID: 1374612
  121. Chong SL, Claussen CM, Dafny N. Nucleus accumbens neuronal activity in freely behaving rats is modulated following acute and chronic methylphenidate administration. Brain Res Bull. 2012 Mar 10;87(4-5):445-456. doi: 10.1016/j.brainresbull.2012.01.004. Epub 2012 Jan 13. PMID: 22248440; PMCID: PMC3295903.
  122. Owens T, Khorooshi R, Wlodarczyk A, Asgari N. Interferons in the central nervous system: a few instruments play many tunes. Glia. 2014 Mar;62(3):339-355. doi: 10.1002/glia.22608. PMID: 24588027.
  123. Dong WQ, Wilson OB, Skolnick MH, Dafny N. Hypothalamic, dorsal raphe and external electrical stimulation modulate noxious evoked responses of habenula neurons. Neuroscience. 1992 Jun;48(4):933-940. doi: 10.1016/0306-4522(92)90281-6. PMID: 1630629.
  124. Frolov A, Reyes-Vasquez C, Dafny N. Behavioral and neuronal recording of the nucleus accumbens in adolescent rats following acute and repetitive exposure to methylphenidate. J Neurophysiol. 2015 Jan 1;113(1):369-379. doi: 10.1152/jn.00633.2013. Epub 2014 Oct 15. PMID: 25318764; PMCID: PMC4294568.
  125. National Academies of Sciences, Engineering, and M., Health and Medicine Division, Board on Health Sciences Policy, Abuse, & Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid. Pain Management and the Opioid Epidemic. Pain Management and the Opioid Epidemic. National Academies Press. 2017.Doi: 10.17226/24781
  126. Priority A, Action G, Giroir B, Mccance, Collins FS, Volkow ND. Reducing Opioid Morbidity and Mortality. 2018.
  127. Ruhm CJ, Batten F, Doleac J, Leive A, Reshef A, Simon D, Skinner J. Deaths of Despair or Drug Problems? 2018.
  128. Qiao JT, Dafny N. Dorsal raphe stimulation modulates nociceptive responses in thalamic parafascicular neurons via an ascending pathway: further studies on ascending pain modulation pathways. Pain. 1988 Jul;34(1):65-74. doi: 10.1016/0304-3959(88)90183-2. PMID: 3405622.
  129. Sarpatwari A, Avorn J, Kesselheim AS. Using a drug-safety tool to prevent competition. N Engl J Med. 2014 Apr 17;370(16):1476-1478. doi: 10.1056/NEJMp1400488. PMID: 24738666.


Comments


Swift, Reliable, and studious. We aim to cherish the world by publishing precise knowledge.

  • asd
  • Brown University Library
  • University of Glasgow Library
  • University of Pennsylvania, Penn Library
  • University of Amsterdam Library
  • The University of British Columbia Library
  • UC Berkeley’s Library
  • MIT Libraries
  • Kings College London University
  • University of Texas Libraries
  • UNSW Sidney Library
  • The University of Hong Kong Libraries
  • UC Santa Barbara Library
  • University of Toronto Libraries
  • University of Oxford Library
  • Australian National University
  • ScienceOpen
  • UIC Library
  • KAUST University Library
  • Cardiff University Library
  • Ball State University Library
  • Duke University Library
  • Rutgers University Library
  • Air University Library
  • UNT University of North Texas
  • Washington Research Library Consortium
  • Penn State University Library
  • Georgetown Library
  • Princeton University Library
  • Science Gate
  • Internet Archive
  • WashingTon State University Library
  • Dimensions
  • Zenodo
  • OpenAire
  • Index Copernicus International
  • icmje
  •  International Scientific Indexing (ISI)
  • Sherpa Romeo
  • ResearchGate
  • Universidad De Lima
  • WorldCat
  • JCU Discovery
  • McGill
  • National University of Singepore Libraries
  • SearchIT
  • Scilit
  • SemantiScholar
  • Base Search
  • VU
  • KB
  • Publons
  • oaji
  • Harvard University
  • sjsu-library
  • UWLSearch
  • Florida Institute of Technology
  • CrossRef
  • LUBsearch
  • Universitat de Paris
  • Technical University of Denmark
  • ResearchBIB
  • Google Scholar
  • Microsoft Academic Search